Marshall Financial Group LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Marshall Financial Group LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,249 shares of the biopharmaceutical company’s stock after acquiring an additional 279 shares during the quarter. Marshall Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $792,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Capital International Investors grew its stake in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after buying an additional 149,124 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $529.24 on Friday. The company has a market cap of $57.14 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock’s fifty day moving average price is $563.19 and its 200 day moving average price is $649.98. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the company posted $9.55 earnings per share. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on REGN shares. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, June 2nd. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, June 2nd. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Finally, UBS Group decreased their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.